The inhalant form of oxytocin that is under development is described as an innovative, heat-stable, and low-cost form of oxytocin that could help manage PPH treatment in resource-poor settings.10,11 Such a novel approach is needed for women who do not deliver in facilities that have appropriate interventions for PPH. The gene discussed is OXT; the disease is pulmonary arterial hypertension.